Insulin-specific tolerance in diabetes.

Area of Science:

• Immunology
• Endocrinology
• Diabetes Research

Background:

• Type 1A diabetes, an immune-mediated condition, is increasingly predictable in humans and preventable in animal models.
• Immunity to insulin is central to understanding both the pathogenesis and potential prevention strategies for type 1A diabetes.
• Insulin autoantibodies and specific T cell responses are key biomarkers and mediators in type 1A diabetes development.

Purpose of the Study:

• To explore the role of insulin immunity in type 1A diabetes prediction and prevention.
• To identify specific insulin peptides involved in disease pathogenesis and therapeutic interventions.
• To evaluate the potential of insulin-based therapies for preventing islet beta-cell destruction.

Main Methods:

• Monitoring insulin autoantibodies for disease prediction in humans and NOD mice.
• Characterizing CD4+ and CD8+ T cell clones recognizing insulin.
• Identifying and determining the structure of insulin peptides bound to MHC molecules.
• Utilizing specific insulin peptides for disease induction or prevention in animal models.
• Conducting clinical trials with insulin and altered peptide ligands.

Main Results:

• Insulin autoantibodies precede diabetes onset in both humans and NOD mice, aiding prediction.
• Insulin-specific T cell clones (CD4+ and CD8+) can transfer diabetes to susceptible recipients.
• Specific insulin peptides have been identified, and their structures with diabetogenic MHC alleles elucidated.
• Therapeutic strategies using insulin or altered peptide ligands are being investigated in clinical trials.

Conclusions:

• Immune responses targeting insulin are fundamental to type 1A diabetes pathogenesis.
• Understanding insulin immunity offers promising avenues for both predicting and preventing type 1A diabetes.
• Targeted immunotherapies based on insulin peptides hold potential for protecting islet beta cells.